- RecruitingPHASE1, PHASE2
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
This study looks at new drug combinations for children and young adults with blood cancers (leukaemia and lymphoma) that have come back or not responded to treatment. It focuses on cancers with specific genetic changes, hoping to find safer and more effective ways to help them.
For: Acute Lymphoblastic Leukemia, in Relapse · Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent · Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RecurrentAustria · Belgium · Denmark - Active not recruitingPHASE3
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
This study looks at new ways to treat children with a type of blood cancer called Acute Myeloid Leukaemia (AML). It compares different chemotherapy drugs, including a drug called gemtuzumab ozogamicin, and different types of stem cell transplants to find the most effective and safest treatments for young patients.
For: Acute Myeloid LeukaemiaAustralia · France · Ireland - Active not recruitingPHASE3
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
This study looks at new ways to treat childhood acute lymphoblastic leukemia (ALL). It explores how to choose the right treatment strength for each child and tests a new way to give a common chemotherapy drug called pegaspargase.
For: Acute Lymphoblastic Leukemia, PediatricUnited States · Canada - RecruitingPHASE3
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
This study looks at a new drug called venetoclax for children, teenagers, and young adults with acute myeloid leukaemia (AML) that has come back. It aims to see if adding venetoclax to standard chemotherapy can help improve their chances of survival.
For: Acute Myeloid LeukemiaUnited States · Australia · Austria - Active not recruitingPHASE2
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
This study is testing a new combination of treatments for children and teenagers with a certain type of acute myeloid leukemia (FLT3-mutated AML). It combines a drug called midostaurin with standard chemotherapy to see if it's safe and effective for these patients.
For: FLT3-mutated Acute Myeloid LeukemiaCzechia · Germany · Italy - RecruitingPHASE3
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
This study looks at new ways to treat childhood leukaemia (ALL) in children and teenagers. It aims to make treatments kinder and more effective by using smart medicines (immunotherapy) and targeting specific cancer features, reducing the need for harsh chemotherapy.
For: Acute Lymphoblastic Leukemia, PediatricAustralia · Austria · Czechia - Active not recruitingPHASE1
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
This study is testing a new drug called Bleximenib alongside standard treatments for acute myeloid leukaemia (AML). It aims to find the safest and most effective dose of Bleximenib when given with other AML medicines, and to understand its side effects.
For: Leukemia, Myeloid, AcuteUnited States · Australia · Canada - Active not recruitingPHASE2
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
This study looks at a new drug, revumenib, with chemotherapy for babies and young children (under 6) with a type of leukaemia that has come back or isn't responding well to treatment, especially if they have a specific gene change.
For: Recurrent Acute Leukemia of Ambiguous Lineage · Recurrent Acute Lymphoblastic Leukemia · Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous LineageUnited States · Canada - Active not recruitingPHASE3
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
This study looks at a new drug, galinpepimut-S, for people with a type of blood cancer called Acute Myeloid Leukaemia (AML) who are in remission. It compares the new drug to standard treatments to see if it helps people live longer.
For: Acute Myeloid LeukemiaUnited States · France · Germany - Active not recruitingPHASE3
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
This study is looking at a new combination of medicines (CPX-351) compared to standard treatment for adults newly diagnosed with a type of blood cancer called Acute Myeloid Leukemia (AML). We want to see if the new combination helps people live longer.
For: Acute Myeloid LeukemiaAustria · Germany - RecruitingPHASE3
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
This study looks at new ways to treat a type of cancer in children and teenagers called lymphoblastic lymphoma. It compares different medications and treatment approaches to find the most effective and safest options for patients in the UK and other countries.
For: Lymphoblastic Lymphoma, ChildhoodAustria · Belgium · China - RecruitingPHASE1, PHASE2
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
This study is for children and young people with cancer that hasn't responded to usual treatments. It tests new medicines that target specific changes in cancer cells, aiming to find the right dose and see if they help. The goal is to find better ways to treat childhood cancer.
For: Pediatric CancerDenmark · France · Italy - Active not recruitingPHASE3
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
This study is for young people with a type of leukaemia called APL. It tests if a treatment combining two drugs, tretinoin and arsenic trioxide, can work as well as standard chemotherapy, but with fewer long-term side effects, especially for the heart.
For: Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARAUnited States · Australia · Canada - RecruitingPHASE2
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
This study helps doctors find the best treatments for people with certain blood cancers like leukaemia. It uses special tests on blood and bone marrow to match patients with personalised treatments or standard care, aiming to improve how cancer treatments are chosen.
For: Acute Myeloid Leukemia · Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm · Acute Myeloid Leukemia Post Cytotoxic TherapyUnited States · Canada · Puerto Rico - RecruitingPHASE2
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
This study looks at new ways to treat a serious type of blood cancer called AML in people aged 18-59. It compares standard treatment with newer drug combinations to see if they work better at shrinking the cancer.
For: Acute Myeloid Leukemia · Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm · Acute Myeloid Leukemia Post Cytotoxic TherapyUnited States · Canada · Puerto Rico - Active not recruitingPHASE1, PHASE2
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
This study looks at new drug combinations for babies with a type of blood cancer called acute lymphoblastic leukaemia (ALL). It explores how well new drugs, bortezomib and vorinostat, work with standard treatments and checks for any side effects, aiming to improve treatment outcomes for these infants.
For: Acute Lymphoblastic LeukemiaUnited States · Canada - Active not recruitingPHASE2, PHASE3
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT
This study looks at new treatments for adults with acute myeloid leukaemia (AML) and high-risk myelodysplastic syndrome (MDS) who are having a stem cell transplant. It aims to improve transplant success and reduce relapse.
For: Acute Myeloid Leukaemia · High-risk Myelodysplastic SyndromeUnited Kingdom - RecruitingPHASE1, PHASE2
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
This study looks at new treatments for children and young adults with specific types of blood cancer that have come back or not responded to previous treatment. It tests a combination of medicines to see if they are safe and work well for those whose cancer has certain genetic changes.
For: Acute Lymphoblastic Leukemia, in Relapse · Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent · Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RecurrentAustria · Belgium · Denmark - RecruitingPHASE1, PHASE2
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
This study is for children and young adults aged 1-21 with specific types of aggressive blood cancers that have come back or not responded to treatment. It tests new drug combinations to see if they're safe and work well for those with certain genetic changes in their cancer.
For: Acute Lymphoblastic Leukemia · Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent · Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RecurrentAustria · Belgium · Denmark